Cytek Biosciences Earnings Estimate
| CTKB Stock | USD 5.13 0.09 1.72% |
Cytek Biosciences Revenue Breakdown by Earning Segment
By analyzing Cytek Biosciences' earnings estimates, investors can diagnose different trends across Cytek Biosciences' analyst sentiment over time as well as compare current estimates against different timeframes. As of February 26, 2025, Gross Profit is expected to decline to about 81.4 M. The current year's Pretax Profit Margin is expected to grow to -0.07
Cytek |
Cytek Biosciences Earnings Estimation Breakdown
The calculation of Cytek Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cytek Biosciences is estimated to be 0.036675 with the future projection ranging from a low of 0.035 to a high of 0.0375. Please be aware that this consensus of annual earnings estimates for Cytek Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.04 Lowest | Expected EPS | 0.04 Highest |
Cytek Biosciences Earnings Projection Consensus
Suppose the current estimates of Cytek Biosciences' value are higher than the current market price of the Cytek Biosciences stock. In this case, investors may conclude that Cytek Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cytek Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 6 | 13.51% | 0.0558 | 0.036675 | -0.08 |
Cytek Biosciences Earnings History
Earnings estimate consensus by Cytek Biosciences analysts from Wall Street is used by the market to judge Cytek Biosciences' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Cytek Biosciences' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Cytek Biosciences Quarterly Gross Profit |
|
Cytek Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Cytek Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cytek Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Cytek Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cytek Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cytek Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cytek Biosciences should always be considered in relation to other companies to make a more educated investment decision.Cytek Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cytek Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | 0.0367 | 0.0558 | 0.0191 | 52 | ||
2024-08-06 | 2024-06-30 | -0.03 | -0.08 | -0.05 | 166 | ||
2024-05-08 | 2024-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2024-02-28 | 2023-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2023-11-07 | 2023-09-30 | 0.03 | -0.05 | -0.08 | 266 | ||
2023-08-08 | 2023-06-30 | 0.03 | -0.03 | -0.06 | 200 | ||
2023-05-09 | 2023-03-31 | 0.03 | -0.05 | -0.08 | 266 | ||
2023-02-28 | 2022-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
2022-11-09 | 2022-09-30 | 0.02 | 0.04 | 0.02 | 100 | ||
2022-08-10 | 2022-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2022-05-11 | 2022-03-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2022-02-23 | 2021-12-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2021-11-08 | 2021-09-30 | 0.02 | 0.02 | 0.0 | 0 | ||
2021-09-03 | 2021-06-30 | 0.02 | 0.07 | 0.05 | 250 | ||
null | null | null | null | null | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.03 | -0.03 | 0 |
About Cytek Biosciences Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cytek Biosciences earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cytek Biosciences estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cytek Biosciences fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -33.6 M | -35.2 M | |
| Retained Earnings Total Equity | -19.6 M | -20.6 M | |
| Earnings Yield | (0.01) | (0.01) | |
| Price Earnings Ratio | (91.41) | (86.84) | |
| Price Earnings To Growth Ratio | 0.21 | 0.22 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.073 | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.